Bilastine

Generic Name: Bilastine

Brand Names: Blexten

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₃₇N_₃O_₃

CAS Number: 202189-78-4

Unique Ingredient Identifier: PA1123N395

Background: Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.

Indication: For symptomatic relief of nasal and non-nasal symptoms of seasonal rhinitis in patients 12 years of age and older and for symptomatic relief in chronic spontaneous urticaria in patients 18 years of age and older .

Associated Conditions: Chronic Spontaneous Urticaria, Seasonal Allergic Rhinitis

Associated Therapies: -

Clinical Trials

Sunshine Biopharma Launches a New Generic Prescription Drug

Sunshine Biopharma's subsidiary, Nora Pharma, launches Bilastine, a generic antihistamine for allergy relief in Canada. The global Bilastine market is projected to grow from $1.3 billion in 2023 to $2.3 billion by 2030. Sunshine Biopharma aims to expand its presence in the Canadian generic drugs market, valued at $9.7 billion in 2023 and expected to reach $19.2 billion by 2032.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy